ArticleBritish journal of cancer2018

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.

Alison M Schram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.